Overview

The focus of this Information Day will be an update of the Agency’s ongoing activities on medicines’ risk management, with the opportunity for an interactive platform to exchange experiences between Regulators and Industry, specifically looking at the safety of medicines and COVID-19 vaccines in women of child-bearing potential (WCBP), during pregnancy and breastfeeding, with special attention on challenges and lessons learned in different settings, such as when developing guidance documents, planning strategies for optimising data collection, measuring the effectiveness of risk minimisation measures (RMMs).
Program Committee
-
Martin Huber, MPH, MPharm Pharmacovigilance Risk Assessment Committee (PRAC) Vice Chair
Federal Institute for Drugs and Medical Devices (BfArM), Germany -
Francesca Day Human Medicines Division, Head of Therapeutic Areas Department (H-TA)
European Medicines Agency , Netherlands -
Evdokia Korakianiti, PhD, MSc Head of Quality and Safety of Medicines
European Medicines Agency, Netherlands -
Georgy Genov, MD Head of PHV Office, ad-interim Head of Quality & Safety of Medicines Department
European Medicines Agency, Netherlands -
Heidi Janssen Head, Endocrinology, Metabolism & Cardiovascular
European Medicines Agency, Netherlands -
Viola Macolic Sarinic, DrSc, MD, MSc PRAC Scientific Lead
European Medicines Agency, Netherlands -
Maria Giovanna Satta Scientific Officer in the Office of Therapies for Neurological and Psychiatric D
European Medicines Agency, Netherlands
Have an account?